Biocon Biologics brings its biosimilar Nepexto to Australia, marking another step in its global autoimmune portfolio expansion.
Biocon Biologics has launched Nepexto, a biosimilar to etanercept, in the Australian market through a partnership with Generic Health. Etanercept, the reference molecule, is used to treat autoimmune conditions such as rheumatoid arthritis, plaque psoriasis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis.
According to The Economic Times, Nepexto works by inhibiting tumor necrosis factor (TNF), a protein that causes inflammation in the body. By mimicking the TNF receptor, it prevents inflammation and slows disease progression in patients with autoimmune disorders. The launch follows regulatory approval and is aligned with Biocon Biologics’ broader strategy to strengthen its biosimilar portfolio in global markets.
The company has already secured approvals in Europe and Australia and is expected to introduce Nepexto in additional geographies soon. This launch reflects Biocon Biologics’ continued focus on expanding access to key biologic treatments worldwide through partnerships and regulatory pathways.
